Following Up On Phathom Pharmaceuticals [Seeking Alpha]
Phathom Pharmaceuticals, Inc. (PHAT)
Last phathom pharmaceuticals, inc. earnings: 3/19 08:31 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Investing Group Leader Follow Summary Today, we're following up on Phathom Pharmaceuticals to see how the marketing rollout of its flagship product, VOQUEZNA, is proceeding. This drug received FDA clearance late last year and is aiming to displace Proton Pump Inhibitors in its market. Management has succeeded in getting the compound covered in most commercial plans and believes VOQUEZNA has at least $3 billion in peak sales potential. However, the company is still seeing a significant quarterly cash burn rate and already has a decent chunk of debt on its balance sheet. Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More » Jonathan Knowles/DigitalVision via Getty Images It has been nearly a year since we last took a look at Phathom Pharmaceuticals NASDAQ: PHAT . We concluded that article on this GI focused concern, saying the stock merited a small " watch item " holding for aggres
Show less
Read more
Impact Snapshot
Event Time:
PHAT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHAT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHAT alerts
High impacting Phathom Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
PHAT
News
- Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.MarketBeat
- Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.MarketBeat
- Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.MarketBeat
- Phathom Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire
- Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.MarketBeat
PHAT
Earnings
- 8/8/24 - Beat
PHAT
Sec Filings
- 8/22/24 - Form SC
- 8/19/24 - Form 8-K
- 8/19/24 - Form 424B5
- PHAT's page on the SEC website